Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12570961 | Methods and compositions for T-cell coculture potency assays and use with cell therapy products | 🖼🧊📄§ | 2026-03-10 | 2042-03-25 | 0 | 31 |
| 12570973 | Compositions and methods for inhibiting intermediate filament tetramerization | 🖼🧊📄§ | 2026-03-10 | 2039-10-08 | 0 | 31 |
| 12570978 | Methods and compositions for macrophage polarization | 🖼🧊📄§ | 2026-03-10 | 2042-11-04 | 0 | 31 |
| 12571000 | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | 🖼🧊📄§ | 2026-03-10 | 2044-01-19 | 0 | 31 |
| 12571002 | Gene therapies for lysosomal disorders | 🖼🧊📄§ | 2026-03-10 | 2041-07-07 | 0 | 31 |
| 12571052 | Immunomodulatory RNA | 🖼🧊📄§ | 2026-03-10 | 2042-05-19 | 0 | 31 |
| 12570627 | Pharmaceutical composition in which production of impurities is suppressed | 🖼🧊📄§ | 2026-03-10 | 2041-05-13 | 0 | 31 |
| 12570632 | Indole derivatives and uses thereof for treating a cancer | 🖼🧊📄§ | 2026-03-10 | 2041-07-06 | 0 | 31 |
| 12570642 | GLP-IR modulating compounds | 🖼🧊📄§ | 2026-03-10 | 2043-10-27 | 0 | 31 |
| 12570655 | Cysteine covalent modifiers of AKT1 and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2045-05-30 | 0 | 31 |
| 12570663 | Crystal forms of an anti-sars CoV-2 agent | 🖼🧊📄§ | 2026-03-10 | 2043-10-05 | 0 | 31 |
| 12570664 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 🖼🧊📄§ | 2026-03-10 | 2045-04-17 | 0 | 31 |
| 12570696 | Tumor-specific polypeptide sequence and use thereof | 🖼🧊📄§ | 2026-03-10 | 2039-11-07 | 0 | 31 |
| 12570699 | Capsid-modified, rAAV3 vector compositions and methods of use in gene therapy of human liver cancer | 🖼🧊📄§ | 2026-03-10 | 2040-12-23 | 0 | 31 |
| 12570700 | SARS-CoV-2 spike receptor binding domain and compositions and methods thereof | 🖼🧊📄§ | 2026-03-10 | 2041-03-25 | 0 | 31 |
| 12570701 | Ferritin nanoparticle displaying an HIV trimer | 🖼🧊📄§ | 2026-03-10 | 2039-06-05 | 0 | 31 |
| 12570705 | Modified ligand-gated ion channels and methods of use | 🖼🧊📄§ | 2026-03-10 | 2041-08-09 | 0 | 31 |
| 12570715 | T cell receptors and methods of use thereof | 🖼🧊📄§ | 2026-03-10 | 2040-07-29 | 0 | 31 |
| 12570712 | Cyclin A1 specific T cell receptors and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2039-02-12 | 0 | 31 |
| 12570714 | Siglec-based chimeric polypeptides and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2040-04-16 | 0 | 31 |
| 12570710 | Targeting LILRB4 with CAR-T or CAR-NK cells in the treatment of cancer | 🖼🧊📄§ | 2026-03-10 | 2038-11-06 | 0 | 31 |
| 12570719 | Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof | 🖼🧊📄§ | 2026-03-10 | 2040-09-25 | 0 | 31 |
| 12570716 | Anti-dinitrophenol chimeric antigen receptors | 🖼🧊📄§ | 2026-03-10 | 2041-02-02 | 0 | 31 |
| 12570717 | Anti-B-cell maturation antigen chimeric antigen receptors with human domains | 🖼🧊📄§ | 2026-03-10 | 2043-11-30 | 0 | 31 |
| 12570724 | Preparation method for biosynthesis of human body structural material | 🖼🧊📄§ | 2026-03-10 | 2044-12-30 | 0 | 31 |
| 12570723 | Recombinant humanized collagen type III alpha-1, and expression vector and use thereof | 🖼🧊📄§ | 2026-03-10 | 2043-12-26 | 0 | 31 |
| 12570731 | Methods for treating cancer with an anti-apo B100 antibody | 🖼🧊📄§ | 2026-03-10 | 2040-11-12 | 0 | 31 |
| 12570730 | Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors | 🖼🧊📄§ | 2026-03-10 | 2040-07-17 | 0 | 31 |
| 12570734 | C-terminal anti-sclerostin antibody variants | 🖼🧊📄§ | 2026-03-10 | 2043-11-30 | 0 | 31 |
| 12570738 | Multi-specific antibody with binding specificity for human IL-13 and IL-17 | 🖼🧊📄§ | 2026-03-10 | 2040-12-18 | 0 | 31 |
| 12570739 | Compositions and methods for improving health through modulating CALHM2 | 🖼🧊📄§ | 2026-03-10 | 2041-10-15 | 0 | 31 |
| 12570743 | BCMA-targeting engineered immune cell and use thereof | 🖼🧊📄§ | 2026-03-10 | 2040-05-06 | 0 | 31 |
| 12570742 | Anti-SIRPα monoclonal antibodies and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2041-11-18 | 0 | 31 |
| 12570741 | NOTCH3 agonist compositions and methods for treating small vessel diseases | 🖼🧊📄§ | 2026-03-10 | 2042-08-31 | 0 | 31 |
| 12570754 | Regimens and methods of treating multiple sclerosis using ofatumumab | 🖼🧊📄§ | 2026-03-10 | 2043-06-08 | 0 | 31 |
| 12570745 | Biomarkers and methods of treating PD-1 and PD-L1 related conditions | 🖼🧊📄§ | 2026-03-10 | 2042-03-04 | 0 | 31 |
| 12570755 | Anti-CD20 antibody and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2043-06-08 | 0 | 31 |
| 12570756 | Methods of use of anti-CD45 antibodies and conjugates thereof | 🖼🧊📄§ | 2026-03-10 | 2041-10-22 | 0 | 31 |
| 12570758 | Chimeric antigen receptors targeting CD33 | 🖼🧊📄§ | 2026-03-10 | 2041-03-31 | 0 | 31 |
| 12570760 | Antigen binding proteins specifically binding PRAME | 🖼🧊📄§ | 2026-03-10 | 2042-05-04 | 0 | 31 |
| 12570765 | Trispecific T cell engagers | 🖼🧊📄§ | 2026-03-10 | 2044-06-28 | 0 | 31 |
| 12570764 | Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2042-09-26 | 0 | 31 |
| 12569578 | RI-labeled humanized antibody | 🖼🧊📄§ | 2026-03-10 | 2042-05-26 | 0 | 31 |
| 12569574 | Proteins with cardioprotective activity | 🖼🧊📄§ | 2026-03-10 | 2040-04-30 | 0 | 31 |
| 12569573 | Enhanced transduction of AAV vectors encoding micrornas | 🖼🧊📄§ | 2026-03-10 | 2040-04-13 | 0 | 31 |
| 12569569 | Nano-delivery system and therapeutic and diagnostic use thereof | 🖼🧊📄§ | 2026-03-10 | 2041-03-15 | 0 | 31 |
| 12569565 | Compositions and methods for the treatment of viral infections | 🖼🧊📄§ | 2026-03-10 | 2043-09-11 | 0 | 31 |
| 12569571 | Salt responsive nanogels and nanoparticles | 🖼🧊📄§ | 2026-03-10 | 2043-06-08 | 0 | 31 |
| 12569572 | Messenger RNA therapy for the treatment of Friedreich's ataxia | 🖼🧊📄§ | 2026-03-10 | 2040-09-10 | 0 | 31 |
| 12569563 | Selective HDAC6 degraders and methods of use thereof | 🖼🧊📄§ | 2026-03-10 | 2040-11-05 | 0 | 31 |